Acquired von Willebrand syndrome in monoclonal gammopathy – A scoping review on hemostatic management
Open Access
- 17 February 2021
- journal article
- review article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (2) , 356-365
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 UpdateSeminars in Thrombosis and Hemostasis, 2013
- Diagnosis and treatment of acquired von Willebrand syndromeThrombosis Research, 2012
- Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical RecognitionMayo Clinic Proceedings, 2012
- Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic ReviewMayo Clinic Proceedings, 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Asking the right questions: Scoping studies in the commissioning of research on the organisation and delivery of health servicesHealth Research Policy and Systems, 2008
- Immune-Mediated Etiology of Acquired von Willebrand Syndrome in Systemic Lupus Erythematosus and in Benign Monoclonal Gammopathy: Therapeutic ImplicationsSeminars in Thrombosis and Hemostasis, 2006
- High dose intravenous immunoglobulin treatment: Mechanisms of actionLiver Transplantation, 2005
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and managementBest Practice & Research Clinical Haematology, 2001